Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL988932 | 0.91 | SLC6A9 (0.57) | SLC6A9CYP3A4GHSR | |
| Hydrochloric Acid SCHEMBL991012 | 0.85 | SLC6A9 (0.57) | SLC6A9CYP3A4 | |
| Hydrochloric Acid SCHEMBL988959 | 0.82 | SLC6A9 (0.47) | SLC6A9CYP3A4 | |
| SCHEMBL989782 | 0.81 | SLC6A9 (0.46) | SLC6A9CYP3A4SCN3AGRIN2C | |
| SCHEMBL4257102 | 0.81 | SLC6A9 (0.51) | SLC6A9CYP3A4OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL989770 | 0.80 | SLC6A9 (0.45) | SLC6A9CYP3A4GRIN2C | |
| Hydrochloric Acid SCHEMBL988257 | 0.79 | SLC6A9 (0.54) | SLC6A9CYP3A4GHSR | |
| SCHEMBL4257107 | 0.78 | SLC6A9 (0.55) | SLC6A9CYP3A4 | |
| Hydrochloric Acid SCHEMBL989674 | 0.77 | SLC6A9 (0.54) | SLC6A9CYP3A4GHSR | |
| SCHEMBL989832 | 0.75 | SLC6A9 (0.84) | SLC6A9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | SLC6A9 73/4885CYP3A4 328/4885GHSR 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.